{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:31:14Z","timestamp":1726759874086},"reference-count":45,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/internalmedicine.52.0992","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T06:47:35Z","timestamp":1383288455000},"page":"2393-2400","source":"Crossref","is-referenced-by-count":9,"title":["Whole-body Insulin Resistance is Associated with Elevated Serum \u03b1-fetoprotein Levels in Patients with Chronic Hepatitis C"],"prefix":"10.2169","volume":"52","author":[{"given":"Yasunori","family":"Kawaguchi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Mizuta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"National Institute of Advanced Industrial Science and Technology, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Motomura","sequence":"additional","affiliation":[{"name":"National Institute of Advanced Industrial Science and Technology, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Isoda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kuwashiro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Oeda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Iwane","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Anzai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwata","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saga Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Lauer G, Walker BD. Hepatitis C virus infection. N Engl J Med 345: 41-52, 2001.","DOI":"10.1056\/NEJM200107053450107"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 362: 2095-2100, 2003.","DOI":"10.1016\/S0140-6736(03)15109-4"},{"key":"3","unstructured":"3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Akuta N, Suzuki F, Kawamura Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79: 1686-1695, 2007.","DOI":"10.1002\/jmv.20979"},{"key":"5","unstructured":"5. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 43: 434-441, 2005."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 46: 92-100, 2011.","DOI":"10.1007\/s00535-010-0293-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chu CW, Hwang SJ, Luo JC, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 32: 240-244, 2001.","DOI":"10.1097\/00004836-200103000-00014"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52: 518-527, 2010.","DOI":"10.1002\/hep.23691"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tamura Y, Yamagiwa S, Aoki Y, et al. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 54: 2530-2537, 2009.","DOI":"10.1007\/s10620-008-0642-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Arase Y, Ikeda K, Suzuki F, et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 79: 1095-1102, 2007.","DOI":"10.1002\/jmv.20866"},{"key":"11","unstructured":"11. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131: 174-181, 1999."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100: 1509-1515, 2005.","DOI":"10.1111\/j.1572-0241.2005.41403.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Romero-G&oacute;mez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128: 636-641, 2005.","DOI":"10.1053\/j.gastro.2004.12.049"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mizuta T, Kawaguchi Y, Eguchi Y, et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 55: 183-189, 2010.","DOI":"10.1007\/s10620-008-0691-2"},{"key":"15","unstructured":"15. Eslam M, Aparcero R, Kawaguchi T, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 34: 297-305, 2011."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125: 1695-1704, 2003.","DOI":"10.1053\/j.gastro.2003.08.032"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fartoux L, Poujol-Robert A, Gu&eacute;chot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54: 1003-1008, 2005.","DOI":"10.1136\/gut.2004.050302"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Muzzi A, Leandro G, Rubbia-Brandt L, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 42: 41-46, 2005.","DOI":"10.1016\/j.jhep.2004.09.022"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460-468, 2004.","DOI":"10.1053\/j.gastro.2003.10.065"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kawaguchi Y, Mizuta T, Oza N, et al. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinaemia in patients with chronic hepatitis C. Liver Int 29: 871-877, 2009.","DOI":"10.1111\/j.1478-3231.2009.01993.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Eguchi Y, Mizuta T, Ishibashi E, et al. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int 29: 213-220, 2009.","DOI":"10.1111\/j.1478-3231.2008.01853.x"},{"key":"22","unstructured":"22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998."},{"key":"23","unstructured":"23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.","DOI":"10.2337\/diacare.22.9.1462"},{"key":"25","unstructured":"25. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 211: 283-286, 1999."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bedossa P, Poynard T; the METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24: 289-293, 1996.","DOI":"10.1002\/hep.510240201"},{"key":"27","unstructured":"27. Exercise and Physical Activity Guide for Health Promotion 2006. http:\/\/www0.nih.go.jp\/eiken\/programs\/pdf\/exercise_guide.pdf"},{"key":"28","unstructured":"28. Hoot N, Aronsky D. Using Bayesian networks to predict survival of liver transplant patients. AMIA Annu Symp Proc 345-349, 2005."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Li Z, Chan C. Inferring pathways and networks with a Bayesian framework. FASEB J 18: 746-748, 2004.","DOI":"10.1096\/fj.03-0475fje"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Groop LC, Bonadonna RC, Shank M, Petrides AS, DeFronzo RA. Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man. J Clin Invest 87: 83-89, 1991.","DOI":"10.1172\/JCI115005"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zhang H, Forman HJ. Redox regulation of &gamma;-glutamyl transpeptidase. Am J Respir Cell Mol Biol 41: 509-515, 2009.","DOI":"10.1165\/rcmb.2009-0169TR"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Bonnet F, Ducluzeau PH, Gastaldelli A, et al. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes 60: 1660-1667, 2011.","DOI":"10.2337\/db10-1806"},{"key":"33","unstructured":"33. Kotani K, Sakane N. Leptin: adiponectin ratio and metabolic syndrome in the general Japanese population. Korean J Lab Med 31: 162-166, 2011."},{"key":"34","unstructured":"34. Finucane FM, Luan J, Wareham NJ, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 52: 2345-2349, 2009."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Oda N, Imamura S, Fujita T, et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 57: 268-273, 2008.","DOI":"10.1016\/j.metabol.2007.09.011"},{"key":"36","unstructured":"36. Lecube A, Hern&aacute;ndez C, Genesc&agrave; J, Sim&oacute; R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 29: 1096-1101, 2006."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-&alpha;-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 98: 2751-2756, 2003.","DOI":"10.1111\/j.1572-0241.2003.08728.x"},{"key":"38","unstructured":"38. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119, 2005.","DOI":"10.1172\/JCI200525102"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kaser S, Moschen A, Kaser A, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 258: 274-280, 2005.","DOI":"10.1111\/j.1365-2796.2005.01543.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Murashima S, Tanaka M, Haramaki M, et al. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 51: 808-812, 2006.","DOI":"10.1007\/s10620-006-3211-2"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Di Bisceglie AM, Stoddard AM, Dienstag JL, et al; HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 53: 1100-1108, 2011.","DOI":"10.1002\/hep.24169"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Akiyama T, Mizuta T, Kawazoe S, et al. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol 17: 914-921, 2011.","DOI":"10.3748\/wjg.v17.i7.914"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Takahashi H, Mizuta T, Eguchi Y, et al. Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol 46: 790-798, 2011.","DOI":"10.1007\/s00535-011-0381-2"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H. The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer 83: 2076-2082, 1998.","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2076::AID-CNCR5>3.0.CO;2-L"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/21\/52_52.0992\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:47:44Z","timestamp":1621446464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/21\/52_52.0992\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":45,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.52.0992","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}